|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
|
US4994443A
(en)
|
1982-12-20 |
1991-02-19 |
The Children's Medical Center Corporation |
Inhibition of angiogenesis
|
|
US5001116A
(en)
|
1982-12-20 |
1991-03-19 |
The Children's Medical Center Corporation |
Inhibition of angiogenesis
|
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US5391485A
(en)
|
1985-08-06 |
1995-02-21 |
Immunex Corporation |
DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
|
|
JPS63500636A
(ja)
|
1985-08-23 |
1988-03-10 |
麒麟麦酒株式会社 |
多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
|
|
US4810643A
(en)
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
KR0166088B1
(ko)
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
|
DE69330750T2
(de)
|
1992-03-04 |
2002-07-04 |
The Regents Of The University Of California, Oakland |
Vergleichende genomhybridisierung
|
|
US5441050A
(en)
|
1992-12-18 |
1995-08-15 |
Neoprobe Corporation |
Radiation responsive surgical instrument
|
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
|
US6114355A
(en)
|
1993-03-01 |
2000-09-05 |
D'amato; Robert |
Methods and compositions for inhibition of angiogenesis
|
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
|
US8143283B1
(en)
|
1993-03-01 |
2012-03-27 |
The Children's Medical Center Corporation |
Methods for treating blood-born tumors with thalidomide
|
|
US5698579A
(en)
|
1993-07-02 |
1997-12-16 |
Celgene Corporation |
Cyclic amides
|
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
|
US5573758A
(en)
|
1995-04-28 |
1996-11-12 |
Allergan |
Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
|
|
US6207639B1
(en)
|
1996-07-12 |
2001-03-27 |
Mcgill University |
Compounds and methods for modulating neurite outgrowth
|
|
US6333307B1
(en)
|
1996-07-12 |
2001-12-25 |
Mcgill University |
Compounds and method for modulating neurite outgrowth
|
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
|
PT2177517E
(pt)
|
1996-07-24 |
2011-11-10 |
Celgene Corp |
2-(2,6-dioxopiperidin-3-il)-ftalimida amino-substituída para redução dos níveis de tnf-alfa
|
|
US5798368A
(en)
|
1996-08-22 |
1998-08-25 |
Celgene Corporation |
Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
|
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
|
JP4214537B2
(ja)
|
1996-08-12 |
2009-01-28 |
セルジーン コーポレーション |
新規な免疫治療薬とこの薬物を使用してサイトカインレベルを抵減する方法
|
|
US5955476A
(en)
|
1997-11-18 |
1999-09-21 |
Celgene Corporation |
Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
|
|
US5874448A
(en)
|
1997-11-18 |
1999-02-23 |
Celgene Corporation |
Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
|
|
US6221585B1
(en)
|
1998-01-15 |
2001-04-24 |
Valigen, Inc. |
Method for identifying genes underlying defined phenotypes
|
|
US20010006973A1
(en)
|
1998-03-16 |
2001-07-05 |
Hon-Wah Man |
1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels
|
|
US6680175B2
(en)
|
1998-05-05 |
2004-01-20 |
Adherex Technologies, Inc. |
Methods for diagnosing and evaluating cancer
|
|
US6472367B1
(en)
|
1998-05-05 |
2002-10-29 |
Adherex Technologies, Inc. |
Compounds and methods for modulating OB-cadherin mediated cell adhesion
|
|
WO1999057149A2
(en)
|
1998-05-05 |
1999-11-11 |
Adherex Technologies, Inc. |
Compounds and methods for modulating nonclassical cadherin-mediated functions
|
|
US6277824B1
(en)
|
1998-07-10 |
2001-08-21 |
Adherex Technologies |
Compounds and methods for modulating adhesion molecule function
|
|
US6322962B1
(en)
|
1998-08-14 |
2001-11-27 |
Board Of Regents, The University Of Texas System |
Sterol-regulated Site-1 protease and assays of modulators thereof
|
|
US6927024B2
(en)
|
1998-11-30 |
2005-08-09 |
Genentech, Inc. |
PCR assay
|
|
CA2361806C
(en)
|
1999-03-18 |
2012-03-13 |
Celgene Corporation |
Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
|
|
WO2001042507A1
(en)
|
1999-12-09 |
2001-06-14 |
Advanced Research & Technology Institute |
Fluorescent in situ rt-pcr
|
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
|
US20030045552A1
(en)
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
|
WO2002070751A1
(en)
|
2001-03-02 |
2002-09-12 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Pcr method
|
|
US7981863B2
(en)
|
2001-09-19 |
2011-07-19 |
Neuronova Ab |
Treatment of Parkinson's disease with PDGF
|
|
US20030194708A1
(en)
|
2002-04-10 |
2003-10-16 |
Minke Binnerts |
Human homolog of crossveinless materials and methods
|
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
EP1551962A4
(en)
|
2002-07-08 |
2007-08-01 |
Merck & Co Inc |
MITOTIC KINESIN BINDING CENTER
|
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
US7122799B2
(en)
|
2003-12-18 |
2006-10-17 |
Palo Alto Research Center Incorporated |
LED or laser enabled real-time PCR system and spectrophotometer
|
|
US7244759B2
(en)
|
2004-07-28 |
2007-07-17 |
Celgene Corporation |
Isoindoline compounds and methods of making and using the same
|
|
US20080051379A1
(en)
|
2004-12-01 |
2008-02-28 |
Trustees Of Boston University |
Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms
|
|
CN101111234A
(zh)
|
2004-12-01 |
2008-01-23 |
细胞基因公司 |
包含免疫调节化合物的组合物及其治疗免疫缺陷疾病的用途
|
|
CA2595711A1
(en)
|
2005-01-25 |
2006-08-03 |
Celgene Corporation |
Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione
|
|
US7504225B2
(en)
|
2005-05-12 |
2009-03-17 |
Applied Genomics, Inc. |
Reagents and methods for use in cancer diagnosis, classification and therapy
|
|
US7776551B2
(en)
|
2005-07-12 |
2010-08-17 |
Ramot At Tel Aviv University Ltd. |
Methods and kits for diagnosing and treating mental retardation
|
|
ES2434946T3
(es)
|
2005-08-31 |
2013-12-18 |
Celgene Corporation |
Compuestos de isoindol imida y composiciones que los comprenden y métodos para usarlo
|
|
US8445198B2
(en)
|
2005-12-01 |
2013-05-21 |
Medical Prognosis Institute |
Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
|
|
WO2007067500A2
(en)
|
2005-12-05 |
2007-06-14 |
Genomic Health, Inc. |
Predictors of patient response to treatment with egfr inhibitors
|
|
US7892740B2
(en)
|
2006-01-19 |
2011-02-22 |
The University Of Chicago |
Prognosis and therapy predictive markers and methods of use
|
|
CA2644716A1
(en)
|
2006-03-13 |
2007-09-27 |
Merck & Co., Inc. |
Ophthalmic compositions for treating ocular hypertension
|
|
US20100284915A1
(en)
|
2006-06-30 |
2010-11-11 |
Hongyue Dai |
Genes associated with chemotherapy response and uses thereof
|
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
WO2008039475A2
(en)
|
2006-09-26 |
2008-04-03 |
The Board Of Trustees Of The University Of Arkansas |
A gene expression profiling based identification of genomic signatures of multiple myeloma and uses thereof
|
|
LT2420498T
(lt)
|
2006-09-26 |
2017-10-25 |
Celgene Corporation |
5-pakeistieji chinazolinono dariniai, kaip priešvėžiniai agentai
|
|
US20090075281A1
(en)
|
2007-07-10 |
2009-03-19 |
Regents Of The University Of California |
Mtbe genes
|
|
EP2235535B1
(en)
|
2007-12-07 |
2014-11-12 |
Celgene Corporation |
Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma
|
|
US20100021437A1
(en)
|
2008-04-07 |
2010-01-28 |
The McLean Hospital Corporation Whitehead Institute for Biomedical Research |
Neural stem cells derived from induced pluripotent stem cells
|
|
WO2009144699A1
(en)
|
2008-05-26 |
2009-12-03 |
Yeda Research And Development Co. Ltd. |
Methods of treating cancer of the central nervous system
|
|
US20100190656A1
(en)
|
2008-08-08 |
2010-07-29 |
Integrated Diagnostics, Inc. |
Breast Cancer Specific Markers and Methods of Use
|
|
US20120035347A1
(en)
|
2009-04-14 |
2012-02-09 |
Schering Corporation |
Interferon-alfa sensitivity biomarkers
|
|
EP2436387B1
(en)
|
2009-05-25 |
2018-07-25 |
Celgene Corporation |
Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
|
|
EP2437752A2
(en)
|
2009-06-03 |
2012-04-11 |
Dicerna Pharmaceuticals, Inc. |
Peptide dicer substrate agents and methods for their specific inhibition of gene expression
|
|
WO2011034931A2
(en)
|
2009-09-15 |
2011-03-24 |
Reactive Surface, Ltd. |
Anti-fouling paints and coatings
|
|
US9217743B2
(en)
|
2009-10-20 |
2015-12-22 |
Tokyo Institute Of Technology |
Screening method utilizing thalidomide-targeting factor
|
|
SG10201501062SA
(en)
|
2010-02-11 |
2015-04-29 |
Celgene Corp |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
|
|
AU2011224166B2
(en)
|
2010-03-12 |
2014-08-21 |
Celgene Corporation |
Methods for the treatment of non-Hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor
|
|
EA201390370A1
(ru)
|
2010-09-15 |
2013-07-30 |
Олмак Дайэгностикс Лимитед |
Молекулярно-диагностический тест для определения онкологического заболевания
|
|
EP2683383B1
(en)
|
2011-03-11 |
2017-11-29 |
Celgene Corporation |
Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2-6-dione in treatment of immune-related and inflammatory diseases
|
|
RS56770B1
(sr)
|
2011-03-11 |
2018-04-30 |
Celgene Corp |
Čvrste forme 3-(5-amino-2-metil-4-okso-4h-hinazolin-3-il)-piperidin-2,6-diona i njihove farmaceutske smeše i upotrebe
|
|
WO2012125405A2
(en)
|
2011-03-11 |
2012-09-20 |
Mayo Foundation For Medical Education And Research |
Methods and materials for assessing responsiveness to lenalidomide, thalidomide, and/or other thalidomide analogs
|
|
EP3096142A3
(en)
|
2011-04-29 |
2017-03-08 |
Celgene Corporation |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
|
|
CA2835179A1
(en)
|
2011-05-06 |
2012-11-15 |
Xentech |
Markers for cancer prognosis and therapy and methods of use
|
|
CA2877736C
(en)
*
|
2012-06-29 |
2021-12-07 |
Celgene Corporation |
Methods for determining drug efficacy using cereblon-associated proteins
|
|
CN114366746A
(zh)
|
2012-08-09 |
2022-04-19 |
细胞基因公司 |
使用氧代异吲哚化合物治疗癌症
|
|
WO2014028445A2
(en)
|
2012-08-14 |
2014-02-20 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
|
US9694015B2
(en)
|
2012-09-10 |
2017-07-04 |
Celgene Corporation |
Methods for the treatment of locally advanced breast cancer
|
|
WO2014204872A2
(en)
|
2013-06-14 |
2014-12-24 |
Complexa, Inc. |
Composition and method for inhibition of pkng from mycobacterium tuberculosis
|
|
WO2015077058A2
(en)
|
2013-11-08 |
2015-05-28 |
The Broad Institute, Inc. |
Compositions and methods for selecting a treatment for b-cell neoplasias
|
|
CA2932120C
(en)
|
2013-12-06 |
2023-09-19 |
Celgene Corporation |
Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
|
|
EP3160486B1
(en)
|
2014-06-27 |
2020-11-18 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
US9713375B1
(en)
|
2015-02-26 |
2017-07-25 |
Brett Einar Rahm |
Collapsible portable table
|
|
US10830762B2
(en)
|
2015-12-28 |
2020-11-10 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
|